Shattuck Labs

This morning, Shattuck provided a company update and announced SL-325, a first-in-class DR3 antagonist antibody targeting the TL1A/DR3 signaling pathway. Initial clinical development will be conducted in inflammatory bowel disease (IBD), with an IND filing expected in Q3 2025. For additional details on SL-325, listen to a replay of our conference call here: https://lnkd.in/gCYTqZzF

In case you missed it, we reported our second quarter 2024 financial results and provided a corporate update. Highlights included updated positive interim data presented at the European Society of Hematology (#EHA) 2024 Annual Meeting from the Phase 1B dose-expansion clinical trial of SL-172154 in frontline HR-MDS and TP53m AML patients. To learn more about our recent advancements and upcoming milestones, read the full press release here: https://lnkd.in/gKbEiywc

In case you missed it, last week, we presented positive data from our ongoing Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Take a listen to our webcast here: https://lnkd.in/gp-wBQWi

Today, we announced additional positive data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. These data further support our differentiated mechanism of action and underscore SL-172154’s emergence as a potentially leading CD47 inhibitor in hematologic malignancies. At 18:00 CEST today, these reaffirming data will be featured in a poster presentation during the EHA 2024 Congress, held both virtually and in Madrid, Spain. For additional details, see our press release: https://lnkd.in/gjXnKRiA

Join Shattuck Labs (#STTK) for an investor call on Fri. June 14 at 7:30 AM ET featuring Dr. Naval G. Daver, MD (MD Anderson Cancer Center) for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. Register here: https://bit.ly/3yPb5yb

In case you missed it, Brad Loncar stopped by our North Carolina offices to talk with our CEO and co-founder, Taylor Schreiber M.D./Ph.D., about our lead asset, SL-172154. Watch the full interview here: https://lnkd.in/gN8VQKVz

We’re heading to the European Hematology Association (EHA) 2024 Congress! We look forward to presenting additional data from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in frontline HR-MDS and TP53m AML patients. These data will be featured in a poster presentation on June 14, 2024, at 18:00 CEST, in Madrid, Spain. For additional details, read the full press release here: https://lnkd.in/gpZktyNb

Today, we reported our first quarter 2024 financial results and provided a corporate update. Highlights included the continued advancement and rapid enrollment across expansion cohorts for our lead clinical program, SL-172154. Looking ahead, we plan to share additional response and initial survival data in June for our frontline AML and HR-MDS cohorts. To learn more about our recent advancements and upcoming milestones, read the full press release here: https://lnkd.in/gSzei6hA

This week, our CEO, Taylor M.D./Ph.D., M.D./Ph.D., will participate in a panel discussion on the evolving immuno-oncology (IO) landscape. The question for this year's session focuses on where we are now and where we are going in IO—and how do we move the needle to get to the next level of clinical benefit for patients? Tune in! For additional information and registration details, please use the following link: https://lnkd.in/edsNM4cd

Later today, Shattuck’s Chief Scientific Officer, George Fromm, Ph.D., will present data in an oral presentation on the potential therapeutic utility of TRIM7 inhibition at the American Association for Cancer Research (#AACR) Annual Meeting 2024 held in San Diego, CA. Tune in at 4:05 pm (PT) to watch the presentation. #ShattuckLabs #Biotechnology